CRSP
CRISPR Therapeutics AG
NASDAQ · Healthcare · Biotechnology · CH
$55.79
−1.24%Margins
Gross margin
-1534.4%
EBITDA margin
-3390.1%
EBIT margin
-3971.5%
Net margin
-3368.7%
FCF margin
-3589.7%
-25.8%
Return on equity
-17.0%
Return on assets
-21.0%
Return on invested capital
0.00x
Asset turnover
-$478.5M
Cash from operations
$24
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026